Depressive Disorder https://greenmedinfo.com/taxonomy/term/1616/all en A 12-week yoga program was effective in increasing parasympathetic tone and reducing depressive symptoms and perceived stress in women. https://greenmedinfo.com/article/12-week-yoga-program-was-effective-increasing-parasympathetic-tone-and-reducin PMID:  J Altern Complement Med. 2017 Jan 4. Epub 2017 Jan 4. PMID: 28051319 Abstract Title:  Effects of Yoga on Heart Rate Variability and Depressive Symptoms in Women: A Randomized Controlled Trial. Abstract:  OBJECTIVES: The purpose of the study was to investigate the effects of a 12-week yoga program on heart rate variability (HRV) and depressive symptoms in depressed women.METHODS: This was a randomized controlled trial. Twenty-six sedentary women scoring≥14 on the Beck Depression Inventory-II were randomized to either the yoga or the control group. The yoga group completed a 12-week yoga program, which took place twice a week for 60 min per session and consisted of breathing exercises, yoga pose practice, and supine meditation/relaxation. The control group was instructed not to engage in any yoga practice and to maintain their usual level of physical activity during the course of the study. Participants&#039; HRV, depressive symptoms, and perceived stress were assessed at baseline and post-test.RESULTS: The yoga group had a significant increase in high-frequency HRV and decreases in low-frequency HRV and low frequency/high frequency ratio after the intervention. The yoga group also reported significantly reduced depressive symptoms and perceived stress. No change was found in the control group.CONCLUSIONS: A 12-week yoga program was effective in increasing parasympathetic tone and reducing depressive symptoms and perceived stress in women with elevated depressive symptoms. Regular yoga practice may be recommended for women to cope with their depressive symptoms and stress and to improve their HRV. <p><a href="https://greenmedinfo.com/article/12-week-yoga-program-was-effective-increasing-parasympathetic-tone-and-reducin" target="_blank">read more</a></p> https://greenmedinfo.com/article/12-week-yoga-program-was-effective-increasing-parasympathetic-tone-and-reducin#comments Depressive Disorder Antidepressive Agents Yoga Human Study Fri, 13 Jan 2017 23:00:26 +0000 greenmedinfo 141984 at https://greenmedinfo.com A 4-week training of aerobic exercise significantly improves functional capacity in patients with major depressive disorder. https://greenmedinfo.com/article/4-week-training-aerobic-exercise-significantly-improves-functional-capacity-pa PMID:  PLoS One. 2016 ;11(5):e0154195. Epub 2016 May 6. PMID: 27152523 Abstract Title:  Antidepressant Efficacy of Adjunctive Aerobic Activity and Associated Biomarkers in Major Depression: A 4-Week, Randomized, Single-Blind, Controlled Clinical Trial. Abstract:  BACKGROUND: Major depressive disorder (MDD) is a highly prevalent, heterogeneous and systemic medical condition. Treatment options are limited, and recent studies have suggested that physical exercise can play an important role in the therapeutics of MDD. The aim of this study was to evaluate the antidepressant efficacy of adjunctive aerobic activity in association with pharmacotherapy (selective serotonin reuptake inhibitor) in symptomatic MDD as well as its association with physiological biomarkers.METHODS: In this randomized, single-blind, add-on, controlled clinical trial, 57 patients (18-55 years of age) were followed-up for 28 days. All patients were drug-free, had been diagnosed with symptomatic MDD and received flexible dose of sertraline during the trial. Patients were randomized to either a 4-week program (4x/week) of add-on aerobic exercise (exercise group, N = 29) or no activity (control group, N = 28). Depression severity was assessed using the Hamilton Rating Scale for Depression (HAM-D) as the primary outcome. At baseline and endpoint, all patients underwent a comprehensive metabolic/cardiopulmonary exercise testing-including determination of maximal oxygen uptake (VO2max), VO2 at the second ventilatory threshold (VO2-VT2), and oxygen pulse (O2 pulse).RESULTS: Depression scores significantly decreased in both groups after intervention. Importantly, patients in the aerobic exercise group required lower sertraline dose compared to the control group (sertraline monotherapy). The VO2max and O2 pulse parameters increased over time only in the exercise group and remained unchanged in the control group.CONCLUSIONS: The present findings suggest that a 4-week training of aerobic exercise significantly improves functional capacity in patients with MDD and may be associated with antidepressant efficacy. This approach may also decrease the need for higher doses of antidepressants to achieve response. Further studies in unmedicated and treatment-resistant MDD patients are needed in order to confirm the utility of short-term aerobic exercise as an alternative therapeutic approach in MDD.TRIAL REGISTRATION: ClinicalTrials.gov NCT02427789. https://greenmedinfo.com/article/4-week-training-aerobic-exercise-significantly-improves-functional-capacity-pa#comments Depression Depressive Disorder Antidepressive Agents Exercise Medication Reduction Human Study Wed, 11 May 2016 23:12:51 +0000 greenmedinfo 127274 at https://greenmedinfo.com A combination of piperine and ferulic acid might be an alternative therapy in the treatment of psychiatric disorders with high efficacy and low side effects. https://greenmedinfo.com/article/combination-piperine-and-ferulic-acid-might-be-alternative-therapy-treatment-p PMID:  Metab Brain Dis. 2015 Jul 30. Epub 2015 Jul 30. PMID: 26220010 Abstract Title:  Synergistic antidepressant-like effect of ferulic acid in combination with piperine: involvement of monoaminergic system. Abstract:  The lifetime prevalence rate for major depressive disorder (MDD) is approximately 17 % for most developed countries around the world. Dietary polyphenols are currently used as an adjuvant therapy to accelerate the therapeutic efficacy on depression. Ferulic acid (FA) or 4-hydroxy-3-methoxy-cinnamic acid (Fig. 1a) is a main polyphenolic component of Chinese herb Radix Angelicae Sinensis, which is found to have antidepressant-like effects through regulating serotonergic and noradrenergic function. The present study examined the synergistic effect of low doses of FA combined with subthreshold dose of piperine, a bioavailability enhancer, on depression-like behaviors in mice, and investigated the possible mechanism. The administration of FA, even in the highest dose tested, reduced immobility time by 60 % in the tail suspension and forced swimming tests (TST and FST) in mice when compared to control. The maximal antidepressant-like effect of FA was obtained with 200 mg/kg. In addition, piperine only produced a weak antidepressant-like effect in the TST and FST. However, the evidence from the interaction analysis suggested a synergistic effect when low doses of FA were combined with a subthreshold dose of piperine. Further neurochemical evidence such as monoamine levels in the frontal cortex, hippocampus, and hypothalamus and measurements of monoamine oxidase activity also supported a synergistic effect of FA and piperine in the enhancement of monoaminergic function. This finding supports the concept that the combination strategy might be an alternative therapy in the treatment of psychiatric disorders with high efficacy and low side effects. https://greenmedinfo.com/article/combination-piperine-and-ferulic-acid-might-be-alternative-therapy-treatment-p#comments Depressive Disorder Ferulic acid Piperine Antidepressive Agents Increased Bioavailability Natural Substance Synergy Animal Study Fri, 31 Jul 2015 00:27:36 +0000 greenmedinfo 119487 at https://greenmedinfo.com A Mediterranean dietary pattern protects against depressive disorders. https://greenmedinfo.com/article/mediterranean-dietary-pattern-protects-against-depressive-disorders PMID:  Arch Gen Psychiatry. 2009 Oct;66(10):1090-8. PMID: 19805699 Abstract Title:  Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Abstract:  CONTEXT: Adherence to the Mediterranean dietary pattern (MDP) is thought to reduce inflammatory, vascular, and metabolic processes that may be involved in the risk of clinical depression. OBJECTIVE: To assess the association between adherence to the MDP and the incidence of clinical depression. DESIGN: Prospective study that uses a validated 136-item food frequency questionnaire to assess adherence to the MDP. The MDP score positively weighted the consumption of vegetables, fruit and nuts, cereal, legumes, and fish; the monounsaturated- to saturated-fatty-acids ratio; and moderate alcohol consumption, whereas meat or meat products and whole-fat dairy were negatively weighted. SETTING: A dynamic cohort of university graduates (Seguimiento Universidad de Navarra/University of Navarra Follow-up [SUN] Project). PARTICIPANTS: A total of 10 094 initially healthy Spanish participants from the SUN Project participated in the study. Recruitment began on December 21, 1999, and is ongoing. MAIN OUTCOME MEASURE: Participants were classified as having incident depression if they were free of depression and antidepressant medication at baseline and reported a physician-made diagnosis of clinical depression and/or antidepressant medication use during follow-up. RESULTS: After a median follow-up of 4.4 years, 480 new cases of depression were identified. The multiple adjusted hazard ratios (95% confidence intervals) of depression for the 4 upper successive categories of adherence to the MDP (taking the category of lowest adherence as reference) were 0.74 (0.57-0.98), 0.66 (0.50-0.86), 0.49 (0.36-0.67), and 0.58 (0.44-0.77) (P for trend https://greenmedinfo.com/article/mediterranean-dietary-pattern-protects-against-depressive-disorders#comments Depression Depressive Disorder Dietary Modification: Mediterranean Diet Human Study Wed, 27 Jan 2010 21:48:45 +0000 greenmedinfo 50258 at https://greenmedinfo.com A recent trial spotlights bright light therapy and its utility beyond the winter months in treating major depressive disorder. https://greenmedinfo.com/article/recent-trial-spotlights-bright-light-therapy-and-its-utility-beyond-winter-mon PMID:  J Fam Pract. 2016 Jul ;65(7):486-8. PMID: 27565102 Abstract Title:  PURLs: Light therapy for nonseasonal major depressive disorder? Abstract:  While bright light therapy already has a place in the treatment of seasonal affective disorder, a recent trial spotlights its utility beyond the winter months. <p><a href="https://greenmedinfo.com/article/recent-trial-spotlights-bright-light-therapy-and-its-utility-beyond-winter-mon" target="_blank">read more</a></p> https://greenmedinfo.com/article/recent-trial-spotlights-bright-light-therapy-and-its-utility-beyond-winter-mon#comments Depressive Disorder Antidepressive Agents Light Therapy Human Study Human: Case Report Thu, 24 Nov 2016 19:12:34 +0000 greenmedinfo 139384 at https://greenmedinfo.com A review of the preventive and therapeutic potential of vitamin C in mental disorders. https://greenmedinfo.com/article/review-preventive-and-therapeutic-potential-vitamin-c-mental-disorders PMID:  Curr Med Sci. 2018 Feb ;38(1):1-10. Epub 2018 Mar 15. PMID: 30074145 Abstract Title:  Preventive and Therapeutic Potential of Vitamin C in Mental Disorders. Abstract:  In this review, we summarize the involvement of vitamin C in mental disorders by presenting available evidence on its pharmacological effects in animal models as well as in clinical studies. Vitamin C, especially its reduced form, has gained interest for its multiple functions in various tissues and organs, including central nervous system (CNS). Vitamin C protects the neuron against oxidative stress, alleviates inflammation, regulates the neurotransmission, affects neuronal development and controls epigenetic function. All of these processes are closely associated with psychopathology. In the past few decades, scientists have revealed that the deficiency of vitamin C may lead to motor deficit, cognitive impairment and aberrant behaviors, whereas supplement of vitamin C has a potential preventive and therapeutic effect on mental illness, such as major depressive disorder (MDD), schizophrenia, anxiety and Alzheimer&#039;s disease (AD). Although several studies support a possible role of vitamin C against mental disorders, more researches are essential to accelerate the knowledge and investigate the mechanism in this field. <p><a href="https://greenmedinfo.com/article/review-preventive-and-therapeutic-potential-vitamin-c-mental-disorders" target="_blank">read more</a></p> https://greenmedinfo.com/article/review-preventive-and-therapeutic-potential-vitamin-c-mental-disorders#comments Alzheimer's Disease Depressive Disorder Schizophrenia Vitamin C Neuroprotective Agents Review Tue, 07 Aug 2018 01:42:50 +0000 greenmedinfo 168583 at https://greenmedinfo.com A water extract of dandelion roots and leaves demonstrated antidepressant effects in an animal model. https://greenmedinfo.com/article/water-extract-dandelion-roots-and-leaves-demonstrated-antidepressant-effects-a PMID:  Pharm Biol. 2014 Aug ;52(8):1028-32. Epub 2014 Mar 10. PMID: 24611722 Abstract Title:  Antidepressant effects of the water extract from Taraxacum officinale leaves and roots in mice. Abstract:  CONTEXT: The leaves and roots of the Taraxacum officinale F. (Asteraceae) is widely used as traditional medicinal herb in Eastern Asian countries.OBJECTIVE: In the present study, the antidepressant-like effects of the water extract of T. officinale (WETO) leaves and roots were investigated in mice using forced swimming test (FST), tail suspension test (TST) and open field test (OFT).MATERIALS AND METHODS: Effects of acute (1-day) and chronic treatments (14-days) with WETO (50, 100 and 200 mg/kg) on the behavioral changes in FST, TST and OFT, and the serum corticotrophin releasing factor (CRF), adrenocorticotropic hormone (ACTH) and corticosterone concentration were assessed in mice.RESULTS: Chronic treatment (14-days) with WETO at the doses of 50, 100 and 200 mg/kg significantly decreased the immobility time in both FST (92.6, 85.1 and 77.4 s) and TST (84.8, 72.1 and 56.9 s). Acute treatment (1-day) with WETO at a dose of 200 mg/kg also markedly decreased the immobility time in both FST (81.7 s) and TST (73.2 s). However, all treatments didnot affect the locomotor activity in the OFT. Moreover, FST induced a significant increase in serum CRF (5.8 ng/ml), ACTH (104.7 pg/ml) and corticosterone levels (37.3 ng/ml). Chronic treatment (14-days) with WETO decreased the serum CRF (200 mg/kg: 3.9 ng/ml) and corticosterone (50 mg/kg: 29.9 ng/ml; 100 mg/kg: 22.5 ng/ml; 200 mg/kg: 19.8 ng/ml) levels.DISCUSSION AND CONCLUSION: These results clearly demonstrated the antidepressant effects of WETO in animal models of behavioral despair and suggested the mechanism involved in the neuroendocrine system. https://greenmedinfo.com/article/water-extract-dandelion-roots-and-leaves-demonstrated-antidepressant-effects-a#comments Dandelion Depression Depressive Disorder Antidepressive Agents Plant Extracts Animal Study Tue, 07 Apr 2015 00:58:53 +0000 greenmedinfo 116660 at https://greenmedinfo.com Adjunctive treatment with huperzine A was associated with a faster resolution of the cognitive symptoms that frequently accompany major depressive disorder. https://greenmedinfo.com/article/adjunctive-treatment-huperzine-was-associated-faster-resolution-cognitive-symp PMID:  Shanghai Arch Psychiatry. 2016 Apr 25 ;28(2):64-71. PMID: 27605862 Abstract Title:  Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Abstract:  BACKGROUND: Acetylcholinesterase (AChE) inhibitors have been shown to be effective in treating cognitive impairment in animal models and in human subjects with major depressive disorder (MDD). Huperzine A (HupA), a Traditional Chinese Medicine derived from a genus of clubmosses known as Huperzineserrata, is a powerful AChE inhibitor that has been used as an adjunctive treatment for MDD, but no meta-analysis on HupA augmentation for MDD has yet been reported.AIM: Conduct a systematic review and meta-analysis of randomized controlled trials (RCTS) about HupA augmentation in the treatment of MDD to evaluate its efficacy and safety.METHODS: Two evaluators independently searched nine English-language and Chinese-language databases, selected relevant studies that met pre-determined inclusion criteria, extracted data about outcome and safety, and conducted quality assessments and data synthesis.RESULTS: Three low-quality RCTs (pooled n=238) from China were identified that compared monotherapy antidepressant treatment for depression versus combined treatment with antidepressants and HupA. Participants in the studies ranged from 16 to 60 years of age. The average duration of adjunctive antidepressant and HupA treatment in the studies was only 6.7 weeks. All three studies were open label and non-blinded, so their overall quality was judged as poor. Meta-analysis of the pooled sample found no significant difference in the improvement in depressive symptoms between the two groups (weighted mean difference: -1.90 (95%CI: -4.23, 0.44), p=0.11). However, the adjunctive HupA group did have significantly greater improvement than the antidepressant only group in cognitive functioning (as assessed by the Wisconsin Card Sorting Test and the Wechsler Memory Scale-Revised) and in quality of life. There was no significant difference in the incidence of adverse drug reactions between groups.CONCLUSIONS: The data available on the effectiveness and safety of adjunctive treatment using HupA in patients with MDD who are receiving antidepressants is insufficient to arrive at a definitive conclusion about its efficacy and safety. Pooling of the data from three low-quality RCTs from China found no advantage of adjunctive HupA in the treatment of depressive symptoms, but adjunctive treatment with HupA was associated with a faster resolution of the cognitive symptoms that frequently accompany MDD. <p><a href="https://greenmedinfo.com/article/adjunctive-treatment-huperzine-was-associated-faster-resolution-cognitive-symp" target="_blank">read more</a></p> https://greenmedinfo.com/article/adjunctive-treatment-huperzine-was-associated-faster-resolution-cognitive-symp#comments Depression Depressive Disorder Huperzine Acetylcholinesterase Inhibitor Review Mon, 17 Sep 2018 20:52:18 +0000 greenmedinfo 170832 at https://greenmedinfo.com AGE accumulation in the skin is independently associated with higher levels of depressive symptoms and depressive disorder. https://greenmedinfo.com/article/age-accumulation-skin-independently-associated-higher-levels-depressive-sympto PMID:  Depress Anxiety. 2016 Jun 6. Epub 2016 Jun 6. PMID: 27271340 Abstract Title:  ADVANCED GLYCATION END PRODUCT (AGE) ACCUMULATION IN THE SKIN IS ASSOCIATED WITH DEPRESSION: THE MAASTRICHT STUDY. Abstract:  BACKGROUND: Depression is a highly prevalent disease with a high morbidity and mortality risk. Its pathophysiology is not entirely clear. However, type 2 diabetes is an important risk factor for depression. One mechanism that may explain this association may include the formation of advanced glycation end products (AGEs). We therefore investigated the association of AGEs with depressive symptoms and depressive disorder. In addition, we examined whether the potential association was present for somatic and/or cognitive symptoms of depression.METHODS: Cross-sectional data were used from the Maastricht Study (N = 862, mean age 59.8± 8.5 years, 55% men). AGE accumulation was measured with skin autofluorescence (SAF) by use of the AGE Reader. Plasma levels of protein-bound pentosidine were measured with high-performance liquid chromatography and fluorescence detection. Nε-(carboxymethyl)lysine (CML) and Nε-(carboxyethyl)lysine (CEL) were measured with ultraperformance liquid chromatography and tandem mass spectrometry. Depressive symptoms and depressive disorder were assessed by the nine-item Patient Health Questionnaire and the Mini-International Neuropsychiatric Interview.RESULTS: Higher SAF was associated with depressive symptoms (β = 0.42, 95% CI 0.12-0.73, P = .007) and depressive disorder (OR = 1.42, 95% CI 1.04-1.95, P = .028) after adjustment for age, sex, type 2 diabetes, smoking, BMI, and kidney function. Plasma pentosidine, CML, and CEL were not independently associated with depressive symptoms and depressive disorder.CONCLUSIONS: This study shows that AGE accumulation in the skin is independently associated with higher levels of depressive symptoms and depressive disorder. This association is present for both somatic and cognitive symptoms of depression. This might suggest that AGEs are involved in the development of depression. https://greenmedinfo.com/article/age-accumulation-skin-independently-associated-higher-levels-depressive-sympto#comments Advanced Glycation End products (AGE) Depression Depressive Disorder Increased Risk Human Study Tue, 21 Jun 2016 22:23:44 +0000 greenmedinfo 128943 at https://greenmedinfo.com An augmentation study of MSI-195 (S-adenosylmethionine) in major depressive disorder. https://greenmedinfo.com/article/augmentation-study-msi-195-s-adenosylmethionine-major-depressive-disorder PMID:  J Psychiatr Res. 2018 Dec ;107:86-96. Epub 2018 Oct 18. PMID: 30368163 Abstract Title:  An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder. Abstract:  We conducted a 6-week double-blind, placebo-controlled, augmentation study comparing the efficacy and safety of MSI-195 800 mg (a proprietary formulation of S-adenosylmethionine) or placebo added to ongoing antidepressant medication (ADT) in acutely depressed subjects with Major Depressive Disorder (MDD) who had experienced an inadequate response to their ongoing ADT (The Horizon Study, ClinicalTrials.gov NCT01912196). There were 234 eligible subjects randomized to either MSI-195 (n = 118) or placebo (n = 116). There were no overall statistically significant differences found between MSI-195 added to ongoing ADT compared to placebo on any of 3 depression-rating instruments (HamD, MADRS, IDS-SR) in the ITT set. MSI-195 was generally safe and well tolerated with predominantly mild gastrointestinal side effects. Post-hoc analyses examined factors that might have affected study outcome. The ITT set was divided into subjects enrolled during the 1st half (first nine months) and 2nd half of the study. MSI-195 added to ongoing ADT was significantly better than placebo on both the HamDand MADRS in the 1st half (p = 0.03 and 0.02 respectively), but not in the 2nd half of the study. Several demographic and clinical characteristics were significantly different between the two study segments including body mass index, pre-randomization symptom severity fluctuation, number of lifetime depressive episodes, and anxious depression sub-type. Thus, the characteristics of the enrolled subjects changed between the 1st and 2nd half of the study. These post-hoc findings highlight the inherent challenges encountered for subject selection in double-blind, placebo controlled trials and compel further investigationof enrollment criteria and moderating factors that affect treatment. The favorable safety profile and clinical benefit observed with MSI-195 in the 1st half of this study warrant further investigation in MDD. <p><a href="https://greenmedinfo.com/article/augmentation-study-msi-195-s-adenosylmethionine-major-depressive-disorder" target="_blank">read more</a></p> https://greenmedinfo.com/article/augmentation-study-msi-195-s-adenosylmethionine-major-depressive-disorder#comments Depressive Disorder S-Adenosylmethionine (SAMe) Antidepressive Agents Human Study Thu, 27 Dec 2018 00:39:24 +0000 greenmedinfo 176507 at https://greenmedinfo.com Astragaloside IV ameliorates neuroinflammation-induced depressive-like behaviors in mice. https://greenmedinfo.com/article/astragaloside-iv-ameliorates-neuroinflammation-induced-depressive-behaviors-mi PMID:  Acta Pharmacol Sin. 2018 May 24. Epub 2018 May 24. PMID: 29795356 Abstract Title:  Astragaloside IV ameliorates neuroinflammation-induced depressive-like behaviors in mice via the PPARγ/NF-κB/NLRP3 inflammasome axis. Abstract:  Major depressive disorder is a common but devastating mental disorder, and recent evidence shows that neuroinflammation may play a pivotal role in the etiology of depression. Astragaloside IV (AS-IV) is an active component purifed from Astragalus membranaceus (Fisch) Bge, which has shown anti-inflammatory, anti-oxidative and anti-apoptotic effects. In this study, we explored whether AS-IV produced antidepressant effects via its inhibition of neuroinflammation in mouse models of depression. Depressive-like behaviors including decreased sucrose consumption, reduced locomotor activity and increased immobility time were induced in mice using repeated restraint stress (RRS). We found that administration of AS-IV (16, 32 and 64 mg·kg·d, ig) significantly attenuated RRS-induced depressive-like behaviors. Furthermore, AS-IV administration significantly reduced the levels of TNF-α and IL-1β, increased PPARγ expression and GSK3β phosphorylation, decreased NF-κB phosphorylation, and reduced NOD-, LRR- and pyrin domain-containingprotein 3 (NLRP3) inflammasome and caspase-1 p20 generation in the hippocampus of the mice. LPS-induced depression-like behaviors were induced byLPS injection (1 mg·kg·d, ip), which were ameliorated by administration of AS-IV (20, 40 mg·kg·d, ig). The results of the LPS-induced mouse model were in accordance with those acquired from the RRS-induced mouse model: LPS injection significantly increased TNF-α and IL-1β expression in the mouse hippocampus, which was reversed by administration of AS-IV. Moreover, administration of AS-IV significantly increased PPARγ expression and GSK3β phosphorylation, and decreased NF-κB phosphorylation and NLRP3 inflammasome. These results suggest that AS-IV is apotential drug against depression, and its antidepressant effects are partially mediated by inhibition of neuroinflammation via the upregulation of PPARγ expression. <p><a href="https://greenmedinfo.com/article/astragaloside-iv-ameliorates-neuroinflammation-induced-depressive-behaviors-mi" target="_blank">read more</a></p> https://greenmedinfo.com/article/astragaloside-iv-ameliorates-neuroinflammation-induced-depressive-behaviors-mi#comments Astragaloside Brain Inflammation Depressive Disorder Anti-Inflammatory Agents Antidepressive Agents Interleukin-1 beta downregulation Tumor Necrosis Factor (TNF) Alpha Inhibitor Animal Study Tue, 25 Sep 2018 00:12:28 +0000 greenmedinfo 171217 at https://greenmedinfo.com Bright light therapy was also more efficacious than placebo in the population of patients with drug-resistant depression. https://greenmedinfo.com/article/bright-light-therapy-was-also-more-efficacious-placebo-population-patients-dru PMID:  J Affect Disord. 2016 Oct ;203:1-8. Epub 2016 Aug 26. PMID: 27267951 Abstract Title:  A sham-controlled randomized trial of adjunctive light therapy for non-seasonal depression. Abstract:  BACKGROUND: The aim of the study was to examine the efficacy and safety of morning bright light therapy (BLT) in the treatment of patients with a current major depressive episode (MDE) in bipolar and unipolar disorder without a seasonal pattern. It was a randomized, sham-controlled trial.METHODS: Adults, ages 18-70 years were randomized to treatment either with BLT or a sham negative ion generator (as a placebo control). The subjects were required to be on a stable and therapeutic dose of psychotropic medication for at least 4 weeks prior to enrollment and their treatment had to be insufficiently effective. Their clinical state was monitored at the baseline and at the end of treatment. The Hamilton Depression Rating Scale-21 items (HDRS-21), Montgomery-Asberg Depression Rating Scale (MADRS), Beck Depression Inventory (BDI-II), Clinical Global Impression-Severity (CGI-S) and Patient Global Impression (PGI) were used. The results were analyzed with an intention-to-treat (ITT) analysis.RESULTS: Ninety-five patients were enrolled (50 diagnosed with bipolar disorder and 45 with unipolar depression). Fifty-two patients were randomized to treatment with BLT and forty-three were in the placebo group (ITT population). Eighty-three subjects completed the study. There were 12 dropouts (5 in the light group and 7 in the placebo group). After 14 days of treatment, a significant improvement was found in all groups (p<p><a href="https://greenmedinfo.com/article/bright-light-therapy-was-also-more-efficacious-placebo-population-patients-dru" target="_blank">read more</a></p> https://greenmedinfo.com/article/bright-light-therapy-was-also-more-efficacious-placebo-population-patients-dru#comments Depressive Disorder Antidepressive Agents Light Therapy Human Study Thu, 24 Nov 2016 00:30:28 +0000 greenmedinfo 139336 at https://greenmedinfo.com Bright light treatment in elderly patients with major depressive disorder improved mood, enhanced sleep efficiency and increased melatonin level. https://greenmedinfo.com/article/bright-light-treatment-elderly-patients-major-depressive-disorder-improved-moo PMID:  Arch Gen Psychiatry. 2011 Jan ;68(1):61-70. PMID: 21199966 Abstract Title:  Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Abstract:  CONTEXT: Major depressive disorder (MDD) in elderly individuals is prevalent and debilitating. It is accompanied by circadian rhythm disturbances associated with impaired functioning of the suprachiasmatic nucleus, the biological clock of the brain. Circadian rhythm disturbances are common in the elderly. Suprachiasmatic nucleus stimulation using bright light treatment (BLT) may, therefore, improve mood, sleep, and hormonal rhythms in elderly patients with MDD.OBJECTIVE: To determine the efficacy of BLT in elderly patients with MDD.DESIGN: Double-blind, placebo-controlled randomized clinical trial.SETTING: Home-based treatment in patients recruited from outpatient clinics and from case-finding using general practitioners&#039; offices in the Amsterdam region.PARTICIPANTS: Eighty-nine outpatients 60 years or older who had MDD underwent assessment at baseline (T0), after 3 weeks of treatment (T1), and 3 weeks after the end of treatment (T2). Intervention Three weeks of 1-hour early-morning BLT (pale blue, approximately 7500 lux) vs placebo (dim red light, approximately 50 lux).MAIN OUTCOME MEASURES: Mean improvement in Hamilton Scale for Depression scores at T1 and T2 using parameters of sleep and cortisol and melatonin levels.RESULTS: Intention-to-treat analysis showed Hamilton Scale for Depression scores to improve with BLT more than placebo from T0 to T1 (7%; 95% confidence interval, 4%-23%; P = .03) and from T0 to T2 (21%; 7%-31%; P = .001). At T1 relative to T0, get-up time after final awakening in the BLT group advanced by 7% (P https://greenmedinfo.com/article/bright-light-treatment-elderly-patients-major-depressive-disorder-improved-moo#comments Depressive Disorder Melatonin Antidepressive Agents Light Therapy Human Study Wed, 24 Aug 2016 15:23:25 +0000 greenmedinfo 133888 at https://greenmedinfo.com Broccoli sprout could be prophylactic vegetable to prevent or minimize the relapse by inflammation in the remission state of depressed patients. https://greenmedinfo.com/article/broccoli-sprout-could-be-prophylactic-vegetable-prevent-or-minimize-relapse-in PMID:  J Nutr Biochem. 2016 Oct 11 ;39:134-144. Epub 2016 Aug 11. PMID: 27833054 Abstract Title:  Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation. Abstract:  Inflammation plays a role in the pathophysiology of depression. Sulforaphane (SFN), an isothiocyanate compound derived from broccoli, is a potent activator of the NF-E2-related factor-2 (Nrf2), which plays a role in inflammation. In this study, we examined whether the prevention effects of SFN in lipopolysaccharide (LPS) induced depression-like behavior in mice. Pretreatment with SFN significantly blocked an increase in the serum tumor necrosis factor-α (TNF-α) level and an increase in microglial activation of brain regions after a single administration of LPS (0.5 mg/kg). Furthermore, SFN significantly potentiated increased serum levels of IL-10 after LPS administration. In the tail-suspension test and forced swimming test, SFN significantly attenuated an increase of the immobility time after LPS administration. In addition, SFN significantly recovered to control levels for LPS-induced alterations in the proteins such as brain-derived neurotrophic factor, postsynaptic density protein 95 and AMPA receptor 1 (GluA1) and dendritic spine density in the brain regions. Finally, dietary intake of 0.1% glucoraphanin (a glucosinolate precursor of SFN) food during the juvenile and adolescence could prevent the onset of LPS-induced depression-like behaviors and dendritic spine changes in the brain regions at adulthood. In conclusion, these findings suggest that dietary intake of SFN-rich broccoli sprout has prophylactic effects on inflammation-related depressive symptoms. Therefore, supplementation of SFN-rich broccoli sprout could be prophylactic vegetable to prevent or minimize the relapse by inflammation in the remission state of depressed patients. <p><a href="https://greenmedinfo.com/article/broccoli-sprout-could-be-prophylactic-vegetable-prevent-or-minimize-relapse-in" target="_blank">read more</a></p> https://greenmedinfo.com/article/broccoli-sprout-could-be-prophylactic-vegetable-prevent-or-minimize-relapse-in#comments Broccoli Sprouts Depression Depressive Disorder Inflammation Sulforaphane Antidepressive Agents Risk Reduction Animal Study Wed, 16 Nov 2016 23:17:23 +0000 greenmedinfo 139138 at https://greenmedinfo.com Cannabinoids prevent depressive-like symptoms and alterations in BDNF expression in a rat model of PTSD. https://greenmedinfo.com/article/cannabinoids-prevent-depressive-symptoms-and-alterations-bdnf-expression-rat-m PMID:  Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 17 ;84(Pt A):129-139. Epub 2018 Feb 17. PMID: 29458190 Abstract Title:  Cannabinoids prevent depressive-like symptoms and alterations in BDNF expression in a rat model of PTSD. Abstract:  Posttraumatic stress disorder (PTSD) is a debilitating condition highly comorbid with depression. The endocannabinoid (eCB) system and brain-derived neurotrophic factor (BDNF) are suggestively involved in both disorders. We examined whether cannabinoids can prevent the long-term depressive-like symptoms induced by exposure to the shock and situational reminders (SRs) model of PTSD. The CB1/2 receptor agonist WIN55,212-2 (0.5 mg/kg; i.p.), the fatty acid hydrolase (FAAH) inhibitor URB597 (0.3 mg/kg, i.p.) or vehicle were administered 2 h after severe shock. Cannabinoids prevented the shock/SRs-induced alterations in social recognition memory, locomotion, passive coping, anxiety-like behavior, anhedonia, fear retrieval, fear extinction and startle response as well as the decrease in BDNF levels in the hippocampus and prefrontal cortex (PFC). Furthermore, significant correlations were found between depressive-like behaviors and BDNF levels in the brain. The findings suggest that cannabinoids may prevent both depressive- and PTSD-like symptoms following exposure to severe stress and that alterations in BDNF levels in the brains&#039; fear circuit are involved in these effects. <p><a href="https://greenmedinfo.com/article/cannabinoids-prevent-depressive-symptoms-and-alterations-bdnf-expression-rat-m" target="_blank">read more</a></p> https://greenmedinfo.com/article/cannabinoids-prevent-depressive-symptoms-and-alterations-bdnf-expression-rat-m#comments Cannabinoids Depressive Disorder Antidepressive Agents Brain-derived neurotrophic factor modulator Animal Study Thu, 29 Mar 2018 18:21:59 +0000 greenmedinfo 161843 at https://greenmedinfo.com